References
- Wolf HK, Tuomilehto J, Kuulasmaa K, et al. Blood pressure levels in the 41 populations of the WHO MONICA Project. J Hum Hypertens 1997;11:733–42
- Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42
- Bonow RO, Smaha LA, Smith SC, Jr., et al. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002;106:1602–5
- Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534–44
- Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003;7:1–94
- Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141–7
- Scheltens T, Bots ML, Numans ME, et al. Awareness, treatment and control of hypertension: the ‘rule of halves’ in an era of risk-based treatment of hypertension. J Hum Hypertens 2007;21:99–106
- Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003
- Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957–63
- Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14:795–803
- Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002;24:1347–57; discussion 6
- Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12: 239–45
- Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357–62
- Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30
- Nelson MR, Reid CM, Ryan P, et al. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006;185:487–9
- Catalan VS, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417–26
- Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005;39:1401–8
- Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23: 2101–7
- Kaplan RC, Psaty BM, Heckbert SR, et al. Blood pressure level and incidence of myocardial infarction among patients treated for hypertension. Am J Public Health 1999;89:1414–17
- Klungel OH, Kaplan RC, Heckbert SR, et al. Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke 2000;31:420–4
- Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000;76:157–63
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97
- Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001;19: 149–55
- Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446–57; discussion 24–5